CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
A new partnership between the Marathon of Hope Cancer Centres Network (MOHCCN) and the Canadian Clinical Trials Group (CCTG) will support three pan-Canadian research teams
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment. "By avoiding surgery, our hope is that the NEEDS trial positively impacts the quality of life of esophageal cancer patients." says the Canadian study lead Dr. Jelena Lukovic is a radiation oncologist at the University Health Network’s Princess Margaret Cancer Centre and Assistant Professor at the University of Toronto.
The CCTG HN10 (EVADER) results were presented at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting in Washington DC. The late breaking results concluded that radiotherapy to some of the lymph node areas can be safely excluded to decrease side effects without compromising tumour control.
The Journal of Clinical Oncology has published ‘Correlative Science in the Cooperative Group System—Re-Engineering for Success,’ which proposes public-private partnerships to increase resources and process innovations to open access to tissue banks
CCTG MAC29 is investigating whether treatment with immunotherapy versus observation in people with early-stage triple-negative breast cancer (TNBC) who had a good response after initial treatment with chemotherapy and immunotherapy is really necessary.
ME17 one of the world’s largest randomized controlled clinical trials using fecal microbiota transplantation (FMT) to improve the effectiveness of the standard of care for advanced melanoma.
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
Doxorubicin + Pembrolizumab vs Doxorubicin for Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score More >>
STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Tumours
Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated with Immuno-Oncotherapeutics (CAN-IMPACT-IO)
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
Stereotactic Body Radiotherapy (SBRT) vs Conventional Palliative Radiotherapy (CRT) for Participants with Painful Non-Spine Bone Metastases
STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study
Please join the Patient Representative Committee in welcoming Michelle Audoin who will be supporting the Breast Disease Site committee.
CCTG would like to welcome our new Patient Representative Haydn Bechthold who will be supporting the Gastrointestinal Disease Site Committee.
A very warm welcome to Jasmine Heuring who has joined the CCTG Patient Representatives Committee and will be supporting the Adolescents & Young Adults and Sarcoma Disease Site Committees. Jasmine is from Winnipeg Manitoba and is a cancer advocate and healthcare analyst.
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
N Engl J Med 388: 2159 - 2170, 2023Eskander RN;Sill MW;Beffa L;Moore RG;Hope JM;Musa FB;Mannel R;Shahin MS;Cantuaria GH;Girda E;Mathews C;Kavecansky J;Leath CA;Gien LT;Hinchcliff EM;Lele SB;Landrum LM;Backes F;O'Cearbhaill RE;Al Baghdadi T;Hill EK;Thaker PH;John VS;Welch S;Fader AN;Powell MA;Aghajanian C;
International Journal of Radiation Oncology*Biology*Physics , 2023Petersen PM;Cook AD;Sydes MR;Clarke N;Cross W;Kynaston H;Logue J;Neville P;Payne H;Parmar MKB;Parulekar W;Persad R;Saad F;Stirling A;Parker CC;Catton C;
The Oncol , 2023Gupta A;Hay AE;Crump M;Djurfeldt MS;Zhu L;Cheung MC;Shepherd LE;Chen BE;Booth CM;
N Engl J Med 388: 1645 - 1656, 2023Partridge AH;Niman SM;Ruggeri M;Peccatori FA;Azim HA;Colleoni M;Saura C;Shimizu C;Sætersdal AB;Kroep JR;Mailliez A;Warner E;Borges VF;Amant F;Gombos A;Kataoka A;Rousset-Jablonski C;Borstnar S;Takei J;Lee JE;Walshe JM;Ruíz-Borrego M;Moore HCF;Saunders C;Bjelic-Radisic V;Susnjar S;Cardoso F;Smith KL;Ferreiro T;Ribi K;Ruddy K;Kammler R;El-Abed S;Viale G;Piccart M;Korde LA;Goldhirsch A;Gelber RD;Pagani O;
J Thoracic Oncol 18: e68 - e69, 2023Piccirillo MC;Chu Q;Bradbury P;Seymour L;
Cancers 15: 1823, 2023Karamouza E;Glasspool RM;Kelly C;Lewsley LA;Carty K;Kristensen GB;Ethier JL;Kagimura T;Yanaihara N;Cecere SC;You B;Boere IA;Pujade-Lauraine E;Ray-Coquard I;Proust-Lima C;Paoletti X;
Supportive Care in Cancer 31: 256, 2023Mian H;Ringash J;Meyer R;Hay AE;Shepherd L;Djurfeldt M;Winter JN;Sussman J;Pater J;Chen BE;Prica A;
